Able Laboratories, Inc. NASD: ABRX

A lawsuit seeking class action status has been filed in the United States District Court for the District of New Jersey on behalf of all purchasers of publicly traded securities of Able Laboratories, Inc. (Nasdaq: ABRX) ("Able Laboratories") between June 25, 2003 and May 23, 2005 (the "Class Period").

The Complaint alleges that Able Laboratories violated federal securities laws by issuing false or misleading public statements. These allegations arise out of the May 19, 2005 and May 23, 2005 announcements in which Able Laboratories (1) suspended the manufacture and distribution of its products on account of questions concerning Able Laboratories' manufacturing practices; (2) recalled all Able Laboratories' products; and (3) withdrew seven of its approved Abbreviated New Drug Applications ("ANDAs"). The Complaint alleges that Able Laboratories acted improperly when its previous positive statements concerning ANDAs failed to disclose or indicate that the testing of Able Laboratories' products did not adhere to standard operating procedures and good manufacturing practices ("GMP"). On this news, the price of Able Laboratories' stock fell from a close of $24.63 per share on May 18, 2005, to close at $6.26 per share on May 19, 2005.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.